This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Funds That Can Continue Rallying

Breakthroughs in understanding of the human genome will result in a flow of new products. Isaly is underweight the big pharmaceutical companies because they have failed to discover many blockbluster drugs lately.

"The sales of the big companies are shrinking and their organizations are shrinking," he says.

A holding is Gilead Sciences (GILD), a biotech that is increasing revenue at a 14% annual rate. The company is a leader in the treatment of HIV. Another holding is Roche (RHHBY), which owns Genentech, a leading biotech producer of cancer drugs.

Live Oak manager Mark Oelschlager looks for unloved companies that have the ability to grow over the long term. He only has 3% of assets in biotech. "Investors are all excited about biotech, and they are neglecting the slow plodders," he says.

Oelschlager likes to find companies with predictable earnings streams. A favorite holding is Stryker (SYK), which makes surgical equipment and implant systems used to repair hips and knees. "This is a dominant company with a very high return on equity," he says.

The slow economy has hurt Stryker's sales, as people postpone elective surgery. But Oelschlager says that the company will continue to achieve long-term growth as an aging popular seeks more medical procedures.

Another holding is McKesson (MCK), which distributes drugs to hospitals and pharmacies. The company is increasing growth by selling software that hospitals can use to automate their operations.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

Stan Luxenberg is a freelance writer specializing in mutual funds and investing. He was executive editor of Individual Investor magazine.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $127.60 0.00%
FB $83.09 0.00%
GOOG $535.38 0.00%
TSLA $205.27 0.00%
YHOO $44.66 0.00%


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs